Photodynamic therapy safe, effective for partial-gland ablation of prostate cancer: Study
New York: Results from a recent study showed padeliporfin vascular-targeted photodynamic therapy (PDT) to be effective for partial-gland ablation of intermediate-risk prostate cancer. The study, based on interim results of a prospective phase IIb trial was presented remotely as part of the canceled 2020 Annual Meeting of the American Urological Association (AUA).
The results demonstrated comparative efficacy in low-risk prostate cancer in this phase II study designed specifically to evaluate vascular-targeted photodynamic therapy for intermediate-risk disease.
Andrew T. Tracey, Memorial Sloan Kettering Cancer Center, New York, and colleagues had aimed to investigate padeliporfin vascular-targeted photodynamic therapy for intermediate-risk prostate cancer.
The study included 50 men with grade group 2 cancer (Gleason 3-4) evaluated via transrectal ultrasound-guided biopsy. They were treated with one to two sessions of unilateral hemiablation using padeliporfin vascular-targeted photodynamic therapy.
A total of 50 men were treated, 49 underwent 3-month biopsy, and 40 of 49 (82%) exhibited no grade group ≥2 cancer in the index lobe at 3 months.
MRI and template, 14-core transrectal ultrasound-guided biopsy (with fusion for Prostate Imaging–Reporting and Data System 3+ lesions) were performed 3 and 12 months after treatment.
Gleason grade 4 or 5 (grade group 2+) cancer was the primary endpoint. Additional data included adverse events and patient-reported quality of life.
Key findings include:
- Of 49, 11 (22%) underwent per-protocol second hemiablation treatment for grade group 2 tumor at 3 months: 9 for residual cancer and 3 for newly identified tumors (n = 2, contralateral; n=1, bilateral).
- A total of 16 men have undergone 12-month biopsy: 15 of 16 (94%) exhibited no Gleason grade 4 or 5 cancer, including 6 of 7 (86%) patients who received two treatments.
- Of the remaining men awaiting 12-month biopsy, 30 of 33 (91%) exhibited no grade group 2+ cancer detected on 3-month biopsy in the treated lobe.
- By 3 months, the median decline in International Index of Erectile Function 5 score from baseline was –1.0 (interquartile range, –7, 0).
- Median improvement in International Index of Erectile Function 5 score was –1.0 (interquartile range, –1 to 5), with pad-free continence observed in 100% of patients.
- Grade 3 treatment-related adverse events occurred in 6 (12%) patients. All procedure-related prostate/pelvic pain resolved by 3 weeks.
"These interim data suggest that padeliporfin vascular-targeted photodynamic therapy may be effective for partial-gland ablation of intermediate-risk prostate cancer, the researchers concluded. "The therapy exerts minimal impact on urinary and sexual function."
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.